• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

高血压治疗中血管紧张素II受体阻滞剂与钙通道阻滞剂固定剂量复方制剂与自由联合用药的药物依从性及临床结局

Medication compliance and clinical outcomes of fixed-dose combinations vs free combinations of an angiotensin II receptor blocker and a calcium channel blocker in hypertension treatment.

作者信息

Tung Ying-Chang, Huang Yu-Chang, Wu Lung-Sheng, Chang Chee-Jen, Chu Pao-Hsien

机构信息

Department of Cardiology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan.

Clinical Informatics and Medical Statistics Research Center, College of Medicine, Chang Gung University, Taipei, Taiwan.

出版信息

J Clin Hypertens (Greenwich). 2017 Oct;19(10):983-989. doi: 10.1111/jch.13035. Epub 2017 May 30.

DOI:10.1111/jch.13035
PMID:28560786
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8030826/
Abstract

Using the National Health Insurance Research Database of Taiwan, the authors identified 1136 patients taking fixed-dose combination and 4544 patients taking free combinations of an angiotensin II receptor blocker and a dihydropyridine calcium channel blocker from January 2009 to December 2012. At a mean follow-up of 2.1 years, the fixed-dose combination was associated with improved medication adherence and persistence and better survival free from major adverse cardiac events and hospitalization for heart failure compared with the free combination regimens.

摘要

作者利用台湾地区国民健康保险研究数据库，识别出2009年1月至2012年12月期间服用血管紧张素II受体阻滞剂和二氢吡啶类钙通道阻滞剂固定剂量复方制剂的1136例患者以及服用自由联合制剂的4544例患者。在平均2.1年的随访期内，与自由联合治疗方案相比，固定剂量复方制剂与更好的用药依从性和持续性相关，且无重大不良心脏事件和因心力衰竭住院的生存期更长。

相似文献

1
Medication compliance and clinical outcomes of fixed-dose combinations vs free combinations of an angiotensin II receptor blocker and a calcium channel blocker in hypertension treatment.高血压治疗中血管紧张素II受体阻滞剂与钙通道阻滞剂固定剂量复方制剂与自由联合用药的药物依从性及临床结局
J Clin Hypertens (Greenwich). 2017 Oct;19(10):983-989. doi: 10.1111/jch.13035. Epub 2017 May 30.
2
Fixed-Dose Combinations of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors.肾素-血管紧张素系统抑制剂与钙通道阻滞剂固定剂量联合用于治疗高血压：血管紧张素受体阻滞剂与血管紧张素转换酶抑制剂的比较
Medicine (Baltimore). 2015 Dec;94(51):e2355. doi: 10.1097/MD.0000000000002355.
3
Clinical outcomes in hypertensive patients treated with a single-pill fixed-dose combination of renin-angiotensin system inhibitor and thiazide diuretic.在接受肾素-血管紧张素系统抑制剂和噻嗪类利尿剂单一固定剂量复方治疗的高血压患者中的临床结局。
J Clin Hypertens (Greenwich). 2018 Dec;20(12):1731-1738. doi: 10.1111/jch.13413. Epub 2018 Oct 30.
4
Diuretic or Beta-Blocker for Hypertensive Patients Already Receiving ACEI/ARB and Calcium Channel Blocker.对于已经接受 ACEI/ARB 和钙通道阻滞剂治疗的高血压患者，使用利尿剂或β受体阻滞剂。
Cardiovasc Drugs Ther. 2017 Dec;31(5-6):535-543. doi: 10.1007/s10557-017-6765-7.
5
Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.血管紧张素转换酶抑制剂或血管紧张素 II 受体阻滞剂联合钙通道阻滞剂降压治疗在预防卒中中的作用。
J Am Pharm Assoc (2003). 2010 Sep-Oct;50(5):e116-25. doi: 10.1331/JAPhA.2010.09234.
6
[One-year persistence of fixed-dose combinations of angiotensin-converting enzyme inhibitor and calcium channel blocker in hypertensive patients].[高血压患者中血管紧张素转换酶抑制剂与钙通道阻滞剂固定剂量组合的一年持续性]
Orv Hetil. 2019 Mar;160(9):343-348. doi: 10.1556/650.2019.31355.
7
Bidirectional adherence changes and associated factors in patients switched from free combinations to equivalent single-pill combinations of antihypertensive drugs.从降压药物自由联合转换为等效单片复方制剂的患者的双向依从性变化及相关因素
Hypertension. 2014 May;63(5):958-67. doi: 10.1161/HYPERTENSIONAHA.113.02455. Epub 2014 Jan 20.
8
Adherence and persistence of single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens.与多片 ARB/CCB 方案相比，单片 ARB/CCB 联合治疗的依从性和持久性。
Curr Med Res Opin. 2010 Dec;26(12):2877-87. doi: 10.1185/03007995.2010.534129. Epub 2010 Nov 11.
9
Follow-up of Antihypertensive Therapy Improves Blood Pressure Control: Results of HYT (HYperTension survey) Follow-up.降压治疗随访可改善血压控制：HYT（高血压调查）随访结果
High Blood Press Cardiovasc Prev. 2017 Sep;24(3):289-296. doi: 10.1007/s40292-017-0208-1. Epub 2017 May 11.
10
Potentially Inappropriate Antihypertensive Prescriptions to Elderly Patients: Results of a Prospective, Observational Study.老年患者潜在不适当的抗高血压药物处方：一项前瞻性观察性研究的结果
Drugs Aging. 2017 Jun;34(6):453-466. doi: 10.1007/s40266-017-0452-z.

引用本文的文献

1
The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension.《2018年韩国高血压学会高血压管理指南》2022年重点更新版
Clin Hypertens. 2023 Feb 15;29(1):11. doi: 10.1186/s40885-023-00234-9.
2
Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review.行政数据库观察性分析中使用的主要不良心血管事件定义：一项系统综述。
BMC Med Res Methodol. 2021 Nov 6;21(1):241. doi: 10.1186/s12874-021-01440-5.
3
Does the Polypill Improve Patient Adherence Compared to Its Individual Formulations? A Systematic Review.与单一制剂相比，复方制剂是否能提高患者的依从性？一项系统评价。
Pharmaceutics. 2020 Feb 22;12(2):190. doi: 10.3390/pharmaceutics12020190.
4
2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension.2018年韩国高血压学会高血压管理指南：第二部分——高血压的诊断与治疗
Clin Hypertens. 2019 Aug 1;25:20. doi: 10.1186/s40885-019-0124-x. eCollection 2019.
5
Long-Term Use of Tamoxifen Is Associated With a Decreased Subsequent Meningioma Risk in Patients With Breast Cancer: A Nationwide Population-Based Cohort Study.他莫昔芬的长期使用与乳腺癌患者后续脑膜瘤风险降低相关：一项基于全国人口的队列研究。
Front Pharmacol. 2019 Jun 12;10:674. doi: 10.3389/fphar.2019.00674. eCollection 2019.
6
Fixed-dose combination pharmacologic therapy to improve hypertension control worldwide: Clinical perspective and policy implications.固定剂量复方药物治疗以改善全球高血压控制：临床视角与政策影响
J Clin Hypertens (Greenwich). 2019 Jan;21(1):4-15. doi: 10.1111/jch.13426. Epub 2018 Nov 27.
7
Treatment adherence among adult hypertensive patients: a cross-sectional retrospective study in primary care in Romania.罗马尼亚初级保健中成年高血压患者的治疗依从性：一项横断面回顾性研究
Patient Prefer Adherence. 2018 Apr 24;12:625-635. doi: 10.2147/PPA.S162965. eCollection 2018.
8
The impact of fixed-dose combination versus free-equivalent combination therapies on adherence for hypertension: a meta-analysis.固定剂量复方制剂与自由等效复方制剂治疗高血压对依从性的影响：一项荟萃分析。
J Clin Hypertens (Greenwich). 2018 May;20(5):902-907. doi: 10.1111/jch.13272. Epub 2018 Apr 27.
9
Fixed-dose vs free-dose combinations for the management of hypertension-An analysis of 81 958 patients.固定剂量与自由剂量联合治疗高血压-对 81958 例患者的分析。
J Clin Hypertens (Greenwich). 2018 Apr;20(4):705-715. doi: 10.1111/jch.13240. Epub 2018 Feb 19.

本文引用的文献

1
Secular Trends in Prescription Patterns of Single-Pill Combinations of an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Plus a Thiazide Diuretic for Hypertensive Patients in Taiwan.台湾高血压患者使用血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂与噻嗪类利尿剂单片复方制剂的处方模式的长期趋势。
Acta Cardiol Sin. 2013 Jan;29(1):49-55.
2
Fixed-Dose Combinations of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors.肾素-血管紧张素系统抑制剂与钙通道阻滞剂固定剂量联合用于治疗高血压：血管紧张素受体阻滞剂与血管紧张素转换酶抑制剂的比较
Medicine (Baltimore). 2015 Dec;94(51):e2355. doi: 10.1097/MD.0000000000002355.
3
2015 guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension.台湾心脏病学会与台湾高血压学会2015年高血压管理指南。
J Chin Med Assoc. 2015 Jan;78(1):1-47. doi: 10.1016/j.jcma.2014.11.005. Epub 2014 Dec 26.
4
Clinical outcomes and healthcare costs in hypertensive patients treated with a fixed-dose combination of amlodipine/valsartan.氨氯地平/缬沙坦固定剂量复方制剂治疗高血压患者的临床疗效和医疗费用
J Clin Hypertens (Greenwich). 2015 Jan;17(1):51-8. doi: 10.1111/jch.12449. Epub 2014 Dec 5.
5
Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.血管紧张素转换酶（ACE）抑制剂与血管紧张素受体阻滞剂治疗原发性高血压的比较。
Cochrane Database Syst Rev. 2014 Aug 22;2014(8):CD009096. doi: 10.1002/14651858.CD009096.pub2.
6
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.固定剂量联合策略对 CVD 患者或高危患者的依从性及相关风险因素的影响：UMPIRE 随机临床试验。
JAMA. 2013 Sep 4;310(9):918-29. doi: 10.1001/jama.2013.277064.
7
Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study.高血压在英格兰、美国和加拿大的全国调查中的患病率、知晓率、治疗率和控制率，以及与卒中及缺血性心脏病死亡率的相关性：一项横断面研究。
BMJ Open. 2013 Aug 30;3(8):e003423. doi: 10.1136/bmjopen-2013-003423.
8
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).2013年欧洲高血压学会（ESH）和欧洲心脏病学会（ESC）动脉高血压管理指南：欧洲高血压学会（ESH）和欧洲心脏病学会（ESC）动脉高血压管理特别工作组
Eur Heart J. 2013 Jul;34(28):2159-219. doi: 10.1093/eurheartj/eht151. Epub 2013 Jun 14.
9
A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.21 个地区 1990-2010 年 67 种致病因素和致病因素群导致的疾病和伤害负担的比较风险评估：全球疾病负担研究 2010 系统分析。
Lancet. 2012 Dec 15;380(9859):2224-60. doi: 10.1016/S0140-6736(12)61766-8.
10
Rationale for triple-combination therapy for management of high blood pressure.三联疗法治疗高血压的原理。
J Clin Hypertens (Greenwich). 2010 Nov;12(11):869-78. doi: 10.1111/j.1751-7176.2010.00360.x. Epub 2010 Aug 20.